Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-VRd versus VRd in transplant-ineligible untreated multiple myeloma
2018-001545-13Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of daratumumab, bortezomib, lenalidomide and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Overall MRD negativity rate. Started Sep 2018; status: active.
02
Drugs
daratumumabbortezomiblenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2018-001545-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001545-13.